Literature DB >> 3956890

Recurrent Clostridium difficile-associated colitis responding to cholestyramine.

D Kunimoto, A B Thomson.   

Abstract

We describe a patient with relapses of Clostridium difficile cytotoxin-positive pseudomembranous colitis (PMC) after treatment with vancomycin, a course of metronidazole and a trial of bacitracin. She remains free of disease after a prolonged course of cholestyramine. We suggest there may be a role for anion-exchange resins in patients with PMC relapsing after vancomycin therapy.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3956890     DOI： 10.1159/000199299

Source DB:  PubMed          Journal:  Digestion        ISSN： 0012-2823            Impact factor:   3.216


  10 in total

1.  Clarification of article on Clostridium difficile--associated colitis.

Authors:  Kenneth Brown
Journal:  Can Fam Physician       Date:  2005-02       Impact factor: 3.275

2.  The role of anion-exchange resins in the treatment of antibiotic-associated pseudomembranous colitis.

Authors:  R E Ariano; G G Zhanel; G K Harding
Journal:  CMAJ       Date:  1990-05-15       Impact factor: 8.262

Review 3.  From stool transplants to next-generation microbiota therapeutics.

Authors:  Elaine O Petrof; Alexander Khoruts
Journal:  Gastroenterology       Date:  2014-01-08       Impact factor: 22.682

4.  Trends in Clostridium difficile Disease: Epidemiology and Intervention.

Authors:  David J Riddle; Erik R Dubberke
Journal:  Infect Med       Date:  2009

Review 5.  Clostridium difficile infection in the intensive care unit.

Authors:  David J Riddle; Erik R Dubberke
Journal:  Infect Dis Clin North Am       Date:  2009-09       Impact factor: 5.982

6.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Relapses or reinfections: analysis of a case of Clostridium difficile-associated colitis by two typing systems.

Authors:  H Kato; N Kato; K Watanabe; K Ueno; Y Sakata; K Fujita
Journal:  Curr Microbiol       Date:  1996-10       Impact factor: 2.188

Review 8.  The clinical significance of antibiotic-associated pseudomembranous colitis in the 1990s.

Authors:  M Andréjak; J L Schmit; A Tondriaux
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

Review 9.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01

10.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.